Trends in glaucoma medication expenditure: Medical expenditure panel survey 2001-2006

Archives of Ophthalmology

Volumn 129, Issue 10, 2011, Pages 1345-1350

  Lam, Byron L ^a   Zheng, D Diane ^b   Davila, Evelyn P ^b   Arheart, Kristopher L ^b   Ocasio, Manuel A ^b   McCollister, Kathryn E ^b   Caban Martinez, Alberto J ^b   Lee, David J ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; FEMALE; GLAUCOMA; HEALTH SURVEY; HIGH SCHOOL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH INSURANCE; TREND STUDY; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIHYPERTENSIVE AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HEALTH SERVICES RESEARCH; HUMANS; INSURANCE COVERAGE; MALE; MEDICARE PART D; MIDDLE AGED; SEX DISTRIBUTION; UNITED STATES;

EID: 80053924491     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.142     Document Type: Article

References (32)

1. Facts about glaucoma. National Eye Institute Web site. http://www.nei.nih.gov/health/glaucoma/glaucoma-facts.asp. Accessed January 22, 2010.
2. Congdon N, O'Colmain B, Klaver CC, et al Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. (Pubitemid 38456282)
3. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754-1760. (Pubitemid 44920172)
4. Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol. 1999;14(3):114-123. (Pubitemid 29474651)
5. Singh K, Lee BL, Wilson MR; GlaucomaModified RAND-Like Methodology Group. A panel assessment of glaucoma management: modification of existing RAND-like methodology for consensus in ophthalmology, part II. results and interpretation. Am J Ophthalmol. 2008;145(3):575-581.
6. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12-19. (Pubitemid 43063883)
7. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
8. Prescription Drug Coverage-General Information. US Department of Health and Human Services Centers for Medicare and Medicaid Services Web site. http://www.cms.gov/PrescriptionDrugCovGenin/. Accessed January 5, 2010.
9. Friedman J. The incidence of the Medicare prescription drug benefit using asset prices to assess its impact on drug makers. Wall Street Journal. February 9, 2009.
10. Ezzati-Rice TM, Rohde F, Greenblatt J. Methodology report No. 22: sample design of the Medical Expenditure Panel Survey Household Component, 1998-2007. http://www.meps.ahrq.gov/mepsweb/data-files/publications/mr22/mr22.pdf. Published March 2008. Accessed October 9, 2009.
11. MEPS-HC response rates by panel. AHRQ Web site. http://meps.ahrq.gov/ mepsweb/survey-comp/hc-response-rate.jsp. Accessed October 7, 2009.
12. Stagnitti MN, Beauregard K, Solis A. Methodology report No. 23: design, methods, and field results of the Medical Expenditure Panel Survey Medical Provider Component (MEPS MPC) - 2006 calendar year data. http://www.meps.ahrq. gov/mepsweb/data-files/publications/mr23/mr23.pdf. Accessed October 9, 2009.
13. MEPS-MPS response rates. AHRQ Web site. http://www.meps.ahrq.gov/mepsweb/ survey-comp/mpc-response-rate.jsp?year=9999&provider-id=All. Accessed September 5, 2010.
14. MEPS HC-113: 2007 full year consolidated data file. AHRQ Web site. http://www.meps.ahrq.gov/mepsweb/data-stats/download-data/pufs/h113/h113doc.pdf. Published November 2009. Accessed September 5, 2010.
15. Data overview. AHRQ Web site. http://www.meps.ahrq.gov/mepsweb/data- stats/data-overview.jsp. Accessed February 16, 2010.
16. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106(4):653-662. (Pubitemid 30194301)
17. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117(5):573-583. (Pubitemid 29218422)
18. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999;106(11):2144-2153. (Pubitemid 30194238)
19. Miller E. Race and the risk of glaucoma. Arch Ophthalmol. 2004;122(6):909-910. (Pubitemid 38736250)
20. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
21. Mason RP, Kosoko O, Wilson MR, et al. National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies, part I: prevalence findings. Ophthalmology. 1989;96(9):1363-1368. (Pubitemid 19231766)
22. Ostermann J, Sloan FA, Herndon L, Lee PP. Racial differences in glaucoma care: the longitudinal pattern of care. Arch Ophthalmol. 2005;123(12):1693-1698. (Pubitemid 41785103)
23. Javitt JC, McBean AM, Nicholson GA, Babish JD, Warren JL, Krakauer H. Undertreatment of glaucoma among black Americans. N Engl J Med. 1991;325(20):1418-1422.
24. Fleming NS. Sociodemographic differences in access to vision care among adults in the United States, 1974-1975. Med Care. 1983;21(11):1076-1088. (Pubitemid 14246462)
25. Chiang YP, Wang F, Javitt JC. Office visits to ophthalmologists and other physicians for eye care among the U.S. population, 1990. Public Health Rep. 1995;110(2):147-153.
26. Brittle C, Bird CE. Literature Review on Effective Sex- and Gender-Based Systems/ Models of Care. Arlington, VA: Office on Women's Health, US Dept of Health and Human Services; 2007.
27. Stein JD, Ayyagari P, Sloan FA, Lee PP. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002. Ophthalmology. 2008;115(8):1315-1319.
28. Netland PA, Landry T, Sullivan EK, et al Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484. (Pubitemid 32904567)
29. Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initiators of topical prostaglandin analogs. Clin Ophthalmol. 2009;3:637-644.
30. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863-868. (Pubitemid 40631506)
31. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983;28(suppl):252-258. (Pubitemid 14197371)
32. Fiscella RG, Geller JL, Gryz LL, Wilensky J, Viana M. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128(4):426-433. (Pubitemid 29479317)